Cabozantinib in Progressive Medullary Thyroid Cancer

20131,203 citationsJournal Articlebronze Open Access

Authors

Rossella Elisei

Martin Schlumberger

В. С. Медведев · Russian Academy of Sciences

Michael C. Kreißl

Bruno Niederle

Ezra E.W. Cohen

Abstract

Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment Renal cell carcinoma treatment Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 29, pp. 3639-3646

DOI: 10.1200/jco.2012.48.4659

Field-Weighted Citation Impact: 65.51